Neoplasms

All Conditions

Digestive System Diseases

Symptoms and General Pathology

Carcinoma

Carcinoma, Hepatocellular

Recurrence

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Disease Attributes

Hematinics

All Drugs and Chemicals

Liver Extracts

Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.

Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.

Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.

Low Dose NK cells ×4 times

Normal Dose NK cells ×4 times

Normal Dose NK cells ×8 times

Wang Guoying, MD

Yang Yang, MD

The purpose of this study is to explore the safety of NK cells from Sibship in patients with recurrent hepatocellular carcinoma after liver transplantation.

Hepatocellular carcinoma (HCC) is one of the indications for the liver transplantation. With the advancement of liver transplantation associated science and technology, the recurrence of tumor posttransplantation has become the principal contradiction to worsen the prognosis and therefore the prevention of recurrence of HCC is the key to improve the efficacy of liver transplantation. Adoptive cellular immunotherapy has been applied in various malignant tumors including HCC and has obtained significant effects. But for patients with liver transplant in immunosuppressed states, to successfully apply the immune cells to prevent and treat HCC relapse after liver transplantation must balance immunosuppression and anti-tumor immunity. It is necessary to consider the safety of adoptive cellular immunotherapy,and it is also necessary to consider the effectiveness of treatment that the immune cells in the immunosuppression state can exert anti-tumor effects. Natural killer cells (NK cells) have MHC-unrestricted killing effect on malignant tumor cells and are not major mediating cells for GVHD, and might be an optimum choice to meet the above requirements.

Patients with confirmed recurrence of hepatocellular carcinoma after liver transplantation at the Third Affiliated Hospital of Sun Yat-sen University were enrolled.Participants in the study will be assigned to one of three treatment arms:

Arm A: Participants will received conventional treatment and low dose of NK cells treatment for 4 times. Arm B: Participants will received conventional treatment and normal dose of NK cells treatment for 4 times. Arm C: Participants will received conventional treatment and normal dose of NK cells treatment for 8 times. The cultured NK cells from the peripheral blood of the same blood type were taken and infused at intervals of two weeks. Periodic liver function recheck and imaging examination were conducted for 6 months after the last NK cells infusion.

Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation

Safety Study of Nature Killer Cells From Sibship to Treat the Recurrence of Hepatocellular Carcinoma After Liver Transplantation

Rash, fever, diarrhea, jaundice etc. leukocyte, platelet, red blood cells reduce, abnormal liver function.Pathological biopsy if necessary.

abnormal liver function，pathological biopsy if necessary.

Third Affiliated Hospital, Sun Yat-Sen University

Department of liver transplantation

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation	NCT02399735	Hepatocellular ...	Low Dose NK cel... Normal Dose NK ... Normal Dose NK ...	18 Years - 65 Years	Third Affiliated Hospital, Sun Yat-Sen University
Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation	NCT02399735	Hepatocellular ...	Low Dose NK cel... Normal Dose NK ... Normal Dose NK ...	18 Years - 65 Years	Third Affiliated Hospital, Sun Yat-Sen University

Spots Global Cancer Trial Database for normal dose nk cells ×4 times